Abstract
Twenty-six eyes of 24 diabetic patients affected by proliferative diabetic retinopathy were randomly treated with diode (810 nm) (13 eyes) and argon-green (514 nm) lasers (13 eyes). In the diode laser group, partial or total regression of neovascularizations was observed in 9 eyes (69.2%) while 4 (30.8%) remained unchanged. In argon-green group seven eyes (53.8%) showed partial or total regression, 5 (38.2%) unchanged and 1 (7.6%) worsened. The mean follow-up time was 6.8 months (SD 2.2) for the diode laser group and 7.8 months (SD 3.2) for the argon-green laser group. The authors discuss the results and the clinical side-effects observed on the basis to the further development of the diode laser in clinical practice.
| Original language | English |
|---|---|
| Pages (from-to) | 233-237 |
| Number of pages | 5 |
| Journal | Lasers and Light in Ophthalmology |
| Volume | 3 |
| Issue number | 3 |
| Publication status | Published - 1990 |
Fingerprint
ASJC Scopus subject areas
- Ophthalmology
Cite this
Argon and diode laser photocoagulation in proliferative diabetic retinopathy : A preliminary report. / Brancato, R.; Bandello, F.; Trabucchi, G.; Leoni, G.; Lattanzio, R.
In: Lasers and Light in Ophthalmology, Vol. 3, No. 3, 1990, p. 233-237.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Argon and diode laser photocoagulation in proliferative diabetic retinopathy
T2 - A preliminary report
AU - Brancato, R.
AU - Bandello, F.
AU - Trabucchi, G.
AU - Leoni, G.
AU - Lattanzio, R.
PY - 1990
Y1 - 1990
N2 - Twenty-six eyes of 24 diabetic patients affected by proliferative diabetic retinopathy were randomly treated with diode (810 nm) (13 eyes) and argon-green (514 nm) lasers (13 eyes). In the diode laser group, partial or total regression of neovascularizations was observed in 9 eyes (69.2%) while 4 (30.8%) remained unchanged. In argon-green group seven eyes (53.8%) showed partial or total regression, 5 (38.2%) unchanged and 1 (7.6%) worsened. The mean follow-up time was 6.8 months (SD 2.2) for the diode laser group and 7.8 months (SD 3.2) for the argon-green laser group. The authors discuss the results and the clinical side-effects observed on the basis to the further development of the diode laser in clinical practice.
AB - Twenty-six eyes of 24 diabetic patients affected by proliferative diabetic retinopathy were randomly treated with diode (810 nm) (13 eyes) and argon-green (514 nm) lasers (13 eyes). In the diode laser group, partial or total regression of neovascularizations was observed in 9 eyes (69.2%) while 4 (30.8%) remained unchanged. In argon-green group seven eyes (53.8%) showed partial or total regression, 5 (38.2%) unchanged and 1 (7.6%) worsened. The mean follow-up time was 6.8 months (SD 2.2) for the diode laser group and 7.8 months (SD 3.2) for the argon-green laser group. The authors discuss the results and the clinical side-effects observed on the basis to the further development of the diode laser in clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=0025053343&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025053343&partnerID=8YFLogxK
M3 - Article
VL - 3
SP - 233
EP - 237
JO - Lasers and Light in Ophthalmology
JF - Lasers and Light in Ophthalmology
SN - 0922-5307
IS - 3
ER -